Penicillin allergy is the most commonly reported drug allergy, with up to 20% of patients carrying this label. When tested, fewer than 10% of such patients were found to be allergic 1 . Incorrect penicillin allergy labels are potentially harmful, with the label increasing the risk of MRSA and C. difficile, longer hospital stays, and mortality 1 . Testing for penicillin allergy involves skin testing (± serum testing), followed by an oral challenge test when these are negative 2 . However, increasing evidence suggests that patients with a 'low risk' history can safely have a direct oral challenge 2 . If this is tolerated without incident, they are 'de-labelled' and advised that they can receive penicillin in the future. We sought to establish the feasibility of offering this abbreviated testing pathway to 'low risk' elective surgical patients who require penicillin for their surgery.
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Incorrect penicillin allergy labels are potentially harmful, with the label increasing the risk of MRSA and C. difficile, longer hospital stays, and mortality 1 . Testing for penicillin allergy involves skin testing (± serum testing), followed by an oral challenge test when these are negative 2 . However, increasing evidence suggests that patients with a 'low risk' history can safely have a direct oral challenge 2 . If this is tolerated without incident, they are 'de-labelled' and advised that they can receive penicillin in the future. We sought to establish the feasibility of offering this abbreviated testing pathway to 'low risk' elective surgical patients who require penicillin for their surgery.
Patients who self-reported a penicillin allergy during routine pre-assessment were screened for eligibility using a questionnaire. Patients with a 'low risk' and meeting the inclusion criteria were offered to attend on a separate day for delabelling with a graded oral amoxicillin challenge (or the index penicillin to which they were allergic). If there were no signs of allergy within the two hours of completing the challenge, patients went home with a 3-day course of amoxicillin, after which they were contacted to rule out any delayed reactions before being formally de-labelled. The patient, surgeon and GP were informed of the results, and the hospital electronic records updated. The notes of patients were reviewed after surgery to assess which antibiotic had been administered intra-operatively.
Penicillin allergy was self-reported in 80 patients, with fifteen eligible for inclusion. To date, 10 of the eligible group have received the graded oral challenge and none has had any immediate or delayed reactions to the amoxicillin. Six of these patients proceeded to have uneventful surgery with penicillin prophylaxis, with four still waiting. Of the 65 ineligible patients, reasons for ineligibility included: high risk symptoms (36/65), did not require penicillin for surgery (20/65), allergic reaction within fifteen years (16/65), declined testing (15/65), insufficient time for testing prior to surgery (7/65), and medical condition preventing inclusion (3/65).
Our preliminary data demonstrates that patients allergic to penicillin can be identified, risk-stratified then de-labelled using an abbreviated testing pathway prior to their planned surgery. These patients then go on to receive penicillin for their surgery, rather than broad spectrum alternatives. This abbreviated pathway has the potential to enable large-scale 'de-labelling' to benefit individuals, and improve the wider antimicrobial stewardship. We conducted a prospective, randomized, placebocontrolled, double-blinded study to investigate the isoflurane and vecuronium requirement in patients who underwent laparoscopic cholecystectomy and received MgSO 4 by two techniques.
Sixty patients of similar demographic variables who underwent laparoscopic cholecystectomy surgery were randomly divided into three groups. Before induction of anaesthesia, the MgSO 4 bolus group (MB) received MgSO 4 50 mg/kg i.v. as a bolus followed by continues infusion of 0.9% NaCl. MgSO 4 bolus plus MgSO 4 infusion group (MI) received bolus MgSO 4 50 mg/kg i.v. followed by 10 mg/kg/h i.v. continuous infusion. The control group (NS) received the same amount of NaCl 0.9% as bolus and infusion. General anaesthesia was induced by standard technique using fentanyl, thiopentone and vecuronium 0.1 mg/kg was administered before intubation. Top up doses of vecuronium 0.025 mg/kg were given under neuromuscular monitoring when the train-of-four count was 2 or more. Anaesthesia was maintained with 33% oxygen, 66% nitrous oxide, 0.5e2% isoflurane through the closed circuit with controlled ventilation to maintain normocapnia. Isoflurane was titrated to maintain bispectral index (BIS) values of 40e60. After an appropriate equilibration period, baseline minimal alveolar concentration (MAC) was determined and subsequent readings were noted at set intervals. Total intraoperative consumption of vecuronium was recorded at the end. Data was analyzed by using one way ANOVA (mean ± SD).
NS isoflurane concentration (1.24 ± 0.14%) was recorded significantly higher (at all time points) during pneumoperitoneum compared to MB (1.01 ± 0.18%) and MI (0.84 ± 0.49%) groups (p<0.01) to maintain haemodynamic parameters within ± 20% of preinduction values. The requirement of isoflurane was found less in MI, compared to MB but was not statistically significant. Mean dose of vecuronium required in Abstracts -e17
